A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study will evaluate the efficacy and safety of trontinemab in participants withbiomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive orfunctional impairment, who are at risk for progression to mild cognitive impairment (MCI)due to AD or dementia due to AD.
Epistemonikos ID: aab98ec502ca76c7f94d92315d87feeab17375ec
First added on: Jul 22, 2026